Периоперационное ведение пациентов с психическими заболеваниями. Методические рекомендации Общероссийской общественной организации «Федерация анестезиологов и реаниматологов», второй пересмотр
#2021-1
PDF_2021-1_19-47
HTML_2021-1_19-47
HTML_2021-1_19-47-S

Ключевые слова

психические заболевания
депрессия
биполярное расстройство
шизофрения
тревожные расстройства
анестезия
интенсивная терапия
периоперационный период
антидепрессанты
нормотимики
антипсихотические препараты

Как цитировать

1.
Заболотских И.Б., Грицан А.И., Лебединский К.М., Мясникова В.В., Муронов А.Е., Шаповалов К.Г. Периоперационное ведение пациентов с психическими заболеваниями. Методические рекомендации Общероссийской общественной организации «Федерация анестезиологов и реаниматологов», второй пересмотр. Вестник интенсивной терапии имени А.И. Салтанова. 2021;(1):19-47. doi:10.21320/1818-474X-2021-1-19-47

Статистика

Просмотров аннотации: 361
PDF_2021-1_19-47 загрузок: 50
HTML_2021-1_19-47 загрузок: 150
HTML_2021-1_19-47-S загрузок: 206
Статистика с 01.07.2024

Язык

English Русский

Мы в соцсетях

Аннотация

Психические расстройства у лиц старше 18 лет достаточно распространены и представлены довольно обширным списком заболеваний. У пациентов с подобной патологией также возникает необходимость проведения вмешательств и манипуляций в условиях анестезии. В статье представлены принципы ведения периоперационного периода у больных с наиболее распространенными психическими заболеваниями — аффективные расстройства, шизофрения, биполярное расстройство, тревожные расстройства, поведенческие синдромы, связанные с физиологическими нарушениями (булимия, анорексия). Отражены профилактика рецидивов психического заболевания и синдрома отмены, профилактика инцидентов, связанных с приемом препаратов, применяемых для терапии психопатологии.
PDF_2021-1_19-47
HTML_2021-1_19-47
HTML_2021-1_19-47-S

Библиографические ссылки

  1. Беккер Р.А., Быков Ю.В. Проблематика проведения общей анестезии на фоне приема психофармакотерапии (Часть I). Портал Consilium Medicum: https://con-med.ru/upload/iblock/eee/psi-for-site-bykov1.pdf. Доступ к статье проверен 25.02.2020. [Becker R.A., Bykov S.E. Problems of conducting general anesthesia while taking psychopharmacotherapy (Part I). Portal Consilium Medicum: https://con-med.ru/upload/iblock/eee/psi-for-site-bykov1.pdf (In Russ)]
  2. Levenson J.L. Psychiatric issues in surgical patients. Part I. General issues, Prim Psychiatry. 2007; 14: 35–39.
  3. Practice Advisory for Preanesthesia Evaluation: An Updated Report by the American Society of Anesthesiologists Task Force on Preanesthesia Evaluation Anesthesiology. 2012; 3(116): 522–538. (https://anesthesiology.pubs.asahq.org/article.aspx?articleid=2443414). DOI: https://doi.org/10.1097/ALN.0b013e31823c1067
  4. Hemmings H.C., Hopkins P.M. Foundations of anesthesia: basic sciences for clinical practice. 2nd ed. Elsevier Health Sciences; 2006: 346–347.
  5. Attri J., Bala N., Chatrath V. Psychiatric patient and anaesthesia. Indian Journal of Anaesthesia. 2012; 56(1): 8–13. DOI: 10.4103/0019-5049.93337
  6. Kessler R.C., Berglund P., Demler O., et al. The Epidemiology of Major Depressive Disorder. JAMA. 2003; 289(23): 3095–105. DOI: 10.1001/jama.289.23.3095
  7. Ghoneim M.M., O’Hara M.W. Depression and postoperative complications: an overview. BMC Surgery. 2016; 16(1). DOI: 10.1186/s12893-016-0120-y
  8. Marschall K.E., Hines R.L. Psychiatric disease/substance abuse/drug overdose. Stoelting’s: Anaesthesia and co-existing diseases. 7th ELSEVIER, 2017: 611–633.
  9. Huyse F.J., Touw D.J., Van Schijndel R.S., et al. Psychotropic Drugs and the Perioperative Period: A Proposal for a Guideline in Elective Surgery. Psychosomatics. 2006; 47(1): 8–22. DOI: 10.1176/appi.psy.47.1.8
  10. Lader M. Benzodiazepine harm: how can it be reduced? British Journal of Clinical Pharmacology. 2012; 77(2): 295–301. DOI: 10.1111/j.1365-2125.2012.04418.x
  11. Nigussie S., Belachew T., Wolancho W. Predictors of preoperative anxiety among surgical patients in Jimma University Specialized Teaching Hospital South Western Ethiopia. BMC Surgery. 2014; 14: 67. DOI: 10.1186/1471-2482-14-67
  12. Schädlich D., Friebel D., Schallner J., et al. Evaluation of haemostasis in children treated with valproic acid. Hamostaseologie. 2010; 30(Suppl. 1): S132–137.
  13. Teich M., Longin E., Dempfle C.-E., Konig S. Factor XIII Deficiency Associated with Valproate Treatment. Epilepsia. 2004; 45(2): 187–189. DOI: 10.1111/j.0013-9580.2004.28302.x
  14. Abdallah C. Considerations in perioperative assessment of valproic acid coagulopathy. Journal of Anaesthesiology Clinical Pharmacology. 2014; 30(1): 7–9. DOI: 10.4103/0970-9185.125685
  15. Hackam D.G., Mrkobrada M. Selective serotonin reuptake inhibitors and brain hemorrhage: A meta-analysis. Neurology. 2013; 79(18): 1862–1865. DOI: 10.1212/wnl.0b013e318271f848
  16. Mahdanian A.A., Rej S., Bacon S.L., et al. Serotonergic antidepressants and perioperative bleeding risk: a systematic review. Expert Opinion on Drug Safety. 2014; 13(6): 695–704. DOI: 10.1517/14740338.2014.908182
  17. Singh I., Achuthan S., Chakrabarti A., et al. Influence of pre-operative use of serotonergic antidepressants (SADs) on the risk of bleeding in patients undergoing different surgical interventions: a meta-analysis. Pharmacoepidemiology and Drug Safety. 2014; 24(3), 237–245. DOI: 10.1002/pds.3632
  18. Eckersley M.J., Sepehripour A.H., Casula R., et al. Do selective serotonin reuptake inhibitors increase the risk of bleeding or mortality following coronary artery bypass graft surgery? A meta-analysis of observational studies. Perfusion. 2018; 33(6): 415–422. DOI: 10.1177/0267659118765933
  19. Seitz D.P., Bell C.M., Gill S.S., et al. Risk of Perioperative Blood Transfusions and Postoperative Complications Associated With Serotonergic Antidepressants in Older Adults Undergoing Hip Fracture Surgery. Journal of Clinical Psychopharmacology. 2013; 33(6): 790–798. DOI: 10.1097/jcp.0b013e3182a58dce
  20. Van Walraven C., Mamdani M.M., Wells P.S., et al. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort. BMJ. 2001; 323(7314): 655–655. DOI: 10.1136/bmj.323.7314.655
  21. Meijer W.E.E., Heerdink E.R., Nolen W.A., et al. Association of Risk of Abnormal Bleeding With Degree of Serotonin Reuptake Inhibition by Antidepressants. Archives of Internal Medicine.2004; 164(21): 2367. DOI: 10.1001/archinte.164.21.2367
  22. Cheng Y.-L., Hu H.-Y., Lin X.-H., et al. Use of SSRI, But Not SNRI, Increased Upper and Lower Gastrointestinal Bleeding. Medicine. 2015; 94(46): e2022. DOI: 10.1097/md.0000000000002022
  23. Shepshelovich D., Schechter A., Calvarysky B., et al. Medication-induced SIADH: distribution and characterization according to medication class. British Journal of Clinical Pharmacology. 2017; 83(8): 1801–1807. DOI: 10.1111/bcp.13256
  24. Lane R.M. SSRIs and hyponatraemia. Br J Clin Pract. 1997; 51(3): 144–146.
  25. Jacob S., Spinier S.A. Hyponatremia Associated with Selective Serotonin-Reuptake Inhibitors in Older Adults. Annals of Pharmacotherapy. 2006; 40(9): 1618–1622. DOI: 10.1345/aph.1g293
  26. Viramontes T.S., Truong H., Linnebur S.A. Antidepressant-Induced Hyponatremia in Older Adults. The Consultant Pharmacist. 2016; 31(3): 139–150. DOI: 10.4140/tcp.n.2016.139
  27. Gandhi S., Shariff S.Z., Al-Jaishi A., et al. Second-Generation Antidepressants and Hyponatremia Risk: A Population-Based Cohort Study of Older Adults. American Journal of Kidney Diseases. 2016; 69(1): 87–96. DOI: 10.1053/j.ajkd.2016.08.020
  28. Goldman M.B. Psychotic Exacerbations and Enhanced Vasopressin Secretion in Schizophrenic Patients With Hyponatremia and Polydipsia. Archives of General Psychiatry. 1997; 54(5): DOI: 10.1001/archpsyc.1997.01830170069010
  29. Raja M. Lithium and Kidney, 60 Years Later. Current Drug Safety. 2011; 6(5): 291–303. DOI: 10.2174/157488611798918737
  30. Ibbeken C., Becker J., Baumgärtel M. Nephrologische Nebenwirkungen einer Langzeittherapie mit Lithium. DMW — Deutsche Medizinische Wochenschrift. 2012; 137(04): 143–148. DOI: 10.1055/s-0031-1298814
  31. Gahr M., Freudenmann R., Connemann B., et al. Nephrotoxizität und Langzeitbehandlung mit Lithium. Psychiatrische Praxis. 2013; 41(01): 15–22. DOI: 10.1055/s-0033-1349490
  32. Tredget J., Kirov A., Kirov G. Effects of chronic lithium treatment on renal function. Journal of Affective Disorders. 2010; 126(3): 436–440. DOI: 10.1016/j.jad.2010.04.018
  33. Sharma S., Joshi S., Chadda R.K. Therapeutic Drug Monitoring of Lithium in Patients With Bipolar Affective Disorder: Experiences From a Tertiary Care Hospital in India. American Journal of Therapeutics. 2009; 16(5): 393–397. DOI: 10.1097/mjt.0b013e31818a88da
  34. Köse G., Arhan E., Unal B., et al. Valproate-Associated Coagulopathies in Children During Short-Term Treatment. Journal of Child Neurology. 2009; 24(12): 1493–1498. DOI: 10.1177/0883073808331084
  35. Koenig S., Gerstner T., Keller A., et al. High incidence of vaproate-induced coagulation disorders in children receiving valproic acid: a prospective study. Blood Coagulation & Fibrinolysis. 2008; 19(5): 375–382. DOI: 10.1097/mbc.0b013e3282f3f9ec
  36. Ugras M., Yakinci C. Protein C, protein S and other pro- and anticoagulant activities among epileptic children using sodium valproate. Brain and Development. 2006; 28(9): 549–553. DOI: 10.1016/j.braindev.2006.03.009
  37. Verrotti A., Greco R., Matera V., et al. Platelet count and function in children receiving sodium valproate. Pediatric Neurology. 1999; 21(3): 611–614. DOI: 10.1016/s0887-8994(99)00060-0
  38. Kreuz W., Linde R., Funk M., et al. Valproate Therapy Induces von Willebrand Disease Type I. Epilepsia. 1992; 33(1): 178–184. DOI: 10.1111/j.1528-1157.1992.tb02303.x
  39. Delgado M.R., Riela A.R., Mills J., et al. Thrombocytopenia Secondary to High Valproate Levels in Children With Epilepsy. Journal of Child Neurology. 1994; 9(3): 311–314. DOI: 10.1177/088307389400900318
  40. Ko C.H., Kong C.K., Tse P.W. Valproic acid and thrombocytopenia: cross-sectional study. Hong Kong Med J. 2001; 7(1): 15–21.
  41. Trannel T.J., Ahmed I., Goebert D. Occurrence of Thrombocytopenia in Psychiatric Patients Taking Valproate. American Journal of Psychiatry. 2001; 158(1): 128–130. DOI: 10.1176/appi.ajp.158.1.128
  42. Vasudev K., Keown P., Gibb I., et al. Hematological Effects of Valproate in Psychiatric Patients. Journal of Clinical Psychopharmacology. 2010; 30(3), 282–285. DOI: 10.1097/jcp.0b013e3181db2684
  43. Bogetto F., Bellino S., Revello R.B., Patria L. Discontinuation Syndrome in Dysthymic Patients Treated with Selective Serotonin Reuptake Inhibitors. CNS Drugs. 2002; 16(4): 273–283. DOI: 10.2165/00023210-200216040-00006
  44. Rosenbaum J.F., Fava M., Hoog S.L., et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biological Psychiatry. 1998; 44(2): 77–87. DOI: 10.1016/s0006-3223(98)00126-7.
  45. Haddad P. Newer Antidepressants and the Discontinuation Syndrome. J Clin Psychiatry. 1997; 58(suppl. 7): 17–22.
  46. Mavandadi S., Ten Have T.R., Katz I.R., Durai U.N.B., et al. Effect of Depression Treatment on Depressive Symptoms in Older Adulthood: The Moderating Role of Pain. Journal of the American Geriatrics Society. 2007; 55(2): 202–211. DOI: 10.1111/j.1532-5415.2007.01042.x
  47. Perks A., Cheema S., Mohanraj R. Anaesthesia and epilepsy. British Journal of Anaesthesia. 2012; 108(4): 562–571. DOI: 10.1093/bja/aes027
  48. Chen M.-J., Zhang W.-J., Guo Z.-L., et al. Withdrawal reaction of carbamazepine after neurovascular decompression for trigeminal neuralgia: A preliminary study. Journal of the Neurological Sciences. 2014; 338(1–2): 43–45. DOI: 10.1016/j.jns.2013.12.013 постоянная ссылка на статью: sci-hub.si/10.1016/j.jns.2013.12.013
  49. Kudoh A., Kimura F., Murakawa T., et al. Perioperative management of patients on long-term administration of psychotropic drugs. Masui. 1993; 42(7): 1056–1064. Japanese. PMID:8350474
  50. Kudoh A., Katagai H., Takase H., Takazawa T. Endocrine Response to Surgical Stress and Postoperative Confusion in Depressed Patients with Alcohol Abuse. Neuropsychobiology. 2004; 50(3): 195–199. DOI: 10.1159/000079969
  51. Donnelly J.G., MacLeod A.D. Hypotension associated with clozapine after cardiopulmonary bypass. Journal of Cardiothoracic and Vascular Anesthesia. 1999; 13(5): 597–599. DOI: 10.1016/s1053-0770(99)90016-2
  52. Desan P.H., Powsner S. Assessment and management of patients with psychiatric disorders. Critical Care Medicine. 2004; 32(Suppl.): S166–S173. DOI: 10.1097/01.ccm.0000120062.91105.51
  53. Kaye A.D., Hoover J.M., Ertner R.A., Sutker P.B. Behavioral and Psychiatric Disorders. In: Fliesher L.A., editor. Anesthesia and Uncommon diseases. 5th Philadelphia: Saunders Elsevier, 2006: 469–492.
  54. Bajwa S.S., Kaur J., Jindal R., et al. Psychiatric diseases: Need for an increased awareness among the anesthesiologists. Journal of Anaesthesiology Clinical Pharmacology. 2011; 27(4): 440. DOI: 10.4103/0970-9185.86572
  55. Krings-Ernst I., Ulrich S., Adli M. Antidepressant treatment with MAO-inhibitors during general and regional anesthesia: A review and case report of spinal anesthesia for lower extremity surgery without discontinuation of tranylcypromine. 2013; 51: 763–770. DOI: 10.5414/CP201898.
  56. Christodoulou G.N., Lykouras E.P. Abrupt lithium discontinuation in manic-depressive patients. Acta Psychiatrica Scandinavica. 1982; 65(5): 310–314. DOI: 10.1111/j.1600-0447.1982.tb00852.x
  57. De Cosmo G., Congedo E., Lai C., et al. Preoperative Psychologic and Demographic Predictors of Pain Perception and Tramadol Consumption Using Intravenous Patient-controlled Analgesia. The Clinical Journal of Pain. 2008; 24(5): 399–405. DOI: 10.1097/ajp.0b013e3181671a08
  58. Royse C., Remedios C., Royse A. High thoracic epidural analgesia reduces the risk of long-term depression in patients undergoing coronary artery bypass surgery. Ann Thorac Cardiovasc Surg. 2007; 13(1): 32–35.
  59. Royse C., Royse A., Soeding P., et al. Prospective randomized trial of high thoracic epidural analgesia for coronary artery bypass surgery. The Annals of Thoracic Surgery. 2003; 75(1): 93–100. DOI: 10.1016/s0003-4975(02)04074-2
  60. Singh M.K., Giles L.L., Nasrallah H.A. Pain Insensitivity in Schizophrenia: Trait or State Marker? Journal of Psychiatric Practice. 2006; 12(2): 90–102. DOI: 10.1097/00131746-200603000-00004
  61. БеккерР.А., Быков Ю.В. Проблематика проведения общей анестезии на фоне приема психофармакотерапии (Часть II). Портал Consilium Medicum: https://con-med.ru/upload/iblock/3c7/psi-for-site-bykov2.pdf Доступ к статье проверен 25.02.2020. [Becker R.A., Bykov S.E. Problems of conducting general anesthesia while taking psychopharmacotherapy (Part II). Portal Consilium Medicum: https://con-med.ru/upload/iblock/3c7/psi-for-site-bykov2.pdf (In Russ)]
  62. Patt R.B., Proper G., Reddy S. The neuroleptics as adjuvant analgesics. Journal of Pain and Symptom Management. 1994; 9(7): 446–453. DOI: 10.1016/0885-3924(94)90201-1
  63. Morgan G.E., Mikhail M.S., Murray M.J. Morgan: Clinical anaesthesiology. 4thed. USA: LANGE International edition. Anesthesia for patients with neurologic and psychiatric diseases. 2008: 647–61.
  64. Hill G.E., Wong K.C., Hodges M.R. Lithium Carbonate and Neuromuscular Blocking Agents. Anesthesiology. 1977; 46(2): 122–125. DOI: 10.1097/00000542-197702000-00008
  65. Fernandes S.C., Braga A.F., Braga F.S., et al. Influence of lithium on the neuromuscular blockade produced by atracurium and cisatracurium. Study on rat phrenic nerve-diaphragm preparations Rev. Bras. Anestesiol. 2007; 57(3): 289–230. DOI: 10.1590/S0034-70942007000300007.
  66. Graudins A., Vossler C., Wang R. Fluoxetine-induced cardiotoxicity with response to bicarbonate therapy. The American Journal of Emergency Medicine. 1997; 15(5): 501–503. DOI: 10.1016/s0735-6757(97)90194-7
  67. Raviña T., Suarez M.L., Mendez-Castrillón J. Fluoxetine-induced QTU interval prolongation, T wave alternans and syncope. Int J Cardiol. 1998; 65(3): 311–313. DOI: 10.1016/s0167-5273(98)00095-3
  68. Erfurth A., Loew M., Dobmeier P., Wendler G. EKG-Veränderungen nach Paroxetin. Der Nervenarzt. 1998; 69(7): 629–631. DOI: 10.1007/s001150050321
  69. De la Torre B.R., Dreher J., Malevany I., et al. Serum Levels and Cardiovascular Effects of Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors in Depressed Patients. Therapeutic Drug Monitoring. 2001; 23(4): 435–440. DOI: 10.1097/00007691-200108000-00019
  70. Pacher P., Kecskemeti V. Cardiovascular Side Effects of New Antidepressants and Antipsychotics: New Drugs, old Concerns? Current Pharmaceutical Design. 2004; 10(20): 2463–2475. DOI: 10.2174/1381612043383872
  71. Khasawneh F.T., Shankar G.S. Minimizing Cardiovascular Adverse Effects of Atypical Antipsychotic Drugs in Patients with Schizophrenia. Cardiology Research and Practice. 2014; 2014: 1–8. DOI: 10.1155/2014/273060
  72. Takeguchi Y., Miyamoto Y., Sone T., Kato H. Severe hypotension during anesthesia in a patient on long-term antidepressant therapy. Masui. 2003; 52(3): 284–287.
  73. Smith F.A., Wittmann C.W., Stern T.A. Medical Complications of Psychiatric Treatment. Critical Care Clinics. 2008; 24(4): 635–656. DOI: 10.1016/j.ccc.2008.05.004
  74. Gugger J.J. Antipsychotic Pharmacotherapy and Orthostatic Hypotension. CNS Drugs. 2011; 25(8): 659–671. DOI: 10.2165/11591710-000000000-00000
  75. Using lithium safely. (1999). Drug and Therapeutics Bulletin. 1999; 37(3): 22–24. DOI: 10.1136/dtb.1999.37322
  76. Rosenqvist M., Bergfeldt L., Aili H., et al. Sinus node dysfunction during long-term lithium treatment. Heart. 1993; 70(4): 371–375. DOI: 10.1136/hrt.70.4.371
  77. Uchiyama Y., Nakao S., Asai T., Shingu K. A case of atropine-resistant bradycardia in a patient on long-term lithium medication. Masui. 2001; 50(11): 1229–1231.
  78. Montalescot G., Levy Y., Hatt P.Y. Serious sinus node dysfunction caused by therapeutic doses of lithium. International Journal of Cardiology. 1984; 5(1): 94–96. DOI: 10.1016/0167-5273(84)90064-0
  79. Mehta N., Vannozzi R. Lithium-induced electrocardiographic changes: A complete review. Clinical Cardiology. 2017; 40(12): 1363–1367. DOI: 10.1002/clc.22822
  80. Mehtonen O.-P., Aranko K., Mälkonen L., et al. A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland. Acta Psychiatrica Scandinavica. 1991; 84(1), 58–64. DOI: 10.1111/j.1600-0447.1991.tb01421.x
  81. Riccioni N., Roni P., Bartolomei C. Lithium-induced sinus node dysfunction. Acta Cardiol. 1983; 38(2): 133–138.
  82. Sprung J., Distel D., Grass J., et al. Cardiovascular collapse during anesthesia in a patient with preoperatively discontinued chronic MAO inhibitor therapy. Journal of Clinical Anesthesia. 1996; 8(8): 662–665. DOI: 10.1016/s0952-8180(96)00175-4
  83. Nakamura S., Takeda K., Nishiyama T., Hanaoka K. General anesthesia for a patient with Noonan’s syndrome and long-term antidepressant therapy. Masui. 2005; 54(8): 901–903.
  84. Takakura K., Nagaya M., Mori M., et al. Refractory Hypotension during Combined General and Epidural Anaesthesia in a Patient on Tricyclic Antidepressants. Anaesthesia and Intensive Care. 2006; 34(1): 111–114. DOI: 10.1177/0310057×0603400108
  85. Tran T.P., Panacek E.A., Rhee K.J., et al. Response to Dopamine vs Norepinephrine in Tricyclic Antidepressant-induced Hypotension. Academic Emergency Medicine. 1997; 4(9): 864–868. DOI: 10.1111/j.1553-2712.1997.tb03811.x
  86. Bovill J. Adverse Drug Interactions in Anesthesia. Journal of Clinical Anesthesia, 1997; 9(6): 3S–13S. DOI: 10.1016/s0952-8180(97)00119-0
  87. Janowsky E.C., Risch C., Janowsky D.S. Effects of Anesthesia on Patients Taking Psychotropic Drugs. Journal of Clinical Psychopharmacology. 1981; 1(1): 14–20. DOI: 10.1097/00004714-198101000-00004
  88. Kudoh A. Perioperative Management for Chronic Schizophrenic Patients. Anesthesia & Analgesia. 2005; 101(6): 1867–1872. DOI: 10.1213/01.ane.0000184123.67853.86
  89. Sawada N., Higashi K., Yanagi F., et al. Sudden onset of bronchospasm and persistent hypotension during spinal anesthesia in a patient on long-term psychotropic therapy. Masui. 1997; 46: 1225–1229.
  90. Dingemanse J., Guentert T., Gieschke R., Stabl M. Modification of the cardiovascular effects of ephedrine by the reversible monoamine oxidase A-inhibitor moclobemide. J Cardiovasc Pharmacol. 1996; 28(6): 856–861.
  91. Folk J.W., Kellner C.H., Beale M.D., et al. Anesthesia for Electroconvulsive Therapy: A Review. The Journal of ECT. 2000; 16(2): 157–170. DOI: 10.1097/00124509-200006000-00007
  92. Boakes A.J., Laurence D.R., Teoh P.C., et al. Interactions between Sympathomimetic Amines and Antidepressant Agents in Man. BMJ. 1973; 1(5849): 311–315. DOI: 10.1136/bmj.1.5849.311
  93. Huyse F.J., Touw D.J., Strack van Schijndel R.J., et al. Measures for patients taking psychotropic drugs who undergo elective surgery. [Article in Dutch] Ned Tijdschr Geneeskd. 2007; 151(6): 353–357.
  94. Desai N., Venkatesh C.R., Kumar S.S. QT prolongation and torsades de pointes with psychotropic agents. Indian J Psychiatry. 2015; 57(3): 305–308. DOI: 10.4103/0019-5545.166619.
  95. Glassman A.H., Bigger J.T. Antipsychotic Drugs: Prolonged QTc Interval, Torsade de Pointes, and Sudden Death. American Journal of Psychiatry. 2001; 158(11): 1774–1782. DOI: 10.1176/appi.ajp.158.11.1774
  96. Riley D.C., Schmeling W.T., Al Wathiqui M.H., et al. Prolongation of the QT interval by volatile anesthetics in chronically instrumented dog. Anesth. Analg. 1988; 67: 741–749.
  97. Lorentz M.N., Vianna B.S.B. Cardiac Dysrhythmias and Anesthesia. Brazilian Journal of Anesthesiology. 2011; 61(6): 798–813. DOI: 10.1016/s0034-7094(11)70090-3
  98. Kudoh A., Ishihara H., Matsuki A. Inhibition of the cortisol response to surgical stress in chronically depressed patients. Journal of Clinical Anesthesia. 2000; 12(5): 383–387. DOI: 10.1016/s0952-8180(00)00179-3
  99. БыковЮ.В., Беккер Р.А., Резников М.К. Депрессии и резистентность. М.: РИОР, 2013. [Bykov Yu.V., Bekker R.A., Reznikov M.K. Depressii i rezistentnost’. Prakticheskoye rukovodstvo. . Moscow: RIOR, 2013. (In Russ)]
  100. Doering L.V., Cross R., Vredevoe D., et al. Infection, depression, and immunity in women after coronary artery bypass: a pilot study of cognitive behavioral therapy. Altern Ther Health Med. 2007; 13(3): 18–21.
  101. Bozic K.J., Lau E., Kurtz S., et al. Patient-related risk factors for postoperative mortality and periprosthetic joint infection in medicare patients undergoing TKA. Clin Orthop Relat Res. 2012; 470(1): 130–137. DOI: 10.1007/s11999-011-2043-3.
  102. Chang S.M., Parney I.F., Mcdermott M., et al. Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project. Journal of Neurosurgery. 2003; 98(6), 1175–1181. DOI: 10.3171/jns.2003.98.6.1175
  103. Gordon R.J., Weinberg A.D., Pagani F.D., et al. Prospective, Multicenter Study of Ventricular Assist Device Infections. Circulation. 2013; 127(6), 691–702. DOI: 10.1161/circulationaha.112.128132
  104. Doering L.V., Moser D.K., Lemankiewicz W., et al. Depression, healing, and recovery from coronary artery bypass surgery. Am J Crit Care. 2005; 14(4): 316–324.
  105. Copeland L.A., Zeber J.E., Pugh M.J., et al. Postoperative Complications in the Seriously Mentally Ill. Annals of Surgery. 2008; 248(1): 31–38. DOI: 10.1097/sla.0b013e3181724f25
  106. Kazmierski J., Kowman M., Banach M., et al. Incidence and predictors of delirium after cardiac surgery: Results from The IPDACS Study. Journal of Psychosomatic Research. 2010; 69(2): 179–185. DOI: 10.1016/j.jpsychores.2010.02.009
  107. Kudoh A. Effect of epidural analgesia on postoperative paralytic ileus in chronic schizophrenia. Regional Anesthesia and Pain Medicine. 2001; 26(5): 456–460. DOI: 10.1053/rapm.2001.25062
  108. Vohra S.B. Convulsions after enflurane in a schizophrenic patient receiving neuroleptics. Canadian Journal of Anaesthesia. 1994; 41(5): 420–422. DOI: 10.1007/bf03009865
  109. Kudoh A., Katagai H., Takazawa T. Anesthesia with ketamine, propofol, and fentanyl decreases the frequency of postoperative psychosis emergence and confusion in schizophrenic patients. Journal of Clinical Anesthesia. 2002; 14(2): 107–110. DOI: 10.1016/s0952-8180(01)00363-4
  110. Barann M., Stamer U.M., Lyutenska M., et al. Effects of opioids on human serotonin transporters. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2014; 388(1): 43–49. DOI: 10.1007/s00210-014-1056-3
  111. Nelson E.M., Philbrick A.M. Avoiding Serotonin Syndrome: The Nature of the Interaction Between Tramadol and Selective Serotonin Reuptake Inhibitors. Annals of Pharmacotherapy. 2012; 46(12): 1712–1716. DOI: 10.1345/aph.1q748
  112. Fox M.A., Jensen C.L., Murphy D.L. Tramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice. The International Journal of Neuropsychopharmacology. 2009; 12(08): DOI: 10.1017/s146114570900011x
  113. Park S.H., Wackernah R.C., Stimmel G.L. Serotonin Syndrome. Journal of Pharmacy Practice. 2013; 27(1): 71–78. DOI: 10.1177/0897190013504957
  114. Сорокина В.В. Диагностика генетических вариантов CYP 2D6 и CYP 2C19 в аспекте применения наркотических анальгетиков. Кубанский научный медицинский вестник. 2009; 6(111): 151–154. [Sorokina V.V. Diagnostics genetic variant СYP 2D6 and CYP 2C19 in aspect of the using narcotic anaesthesiatizing. Kuban Scientific Medical Bulletin. 2009; 6(111): 151–154. (In Russ)]
  115. Abadie D., Rousseau V., Logerot S., et al. Serotonin Syndrome. Journal of Clinical Psychopharmacology. 2015; 35(4): 382–388. DOI: 10.1097/jcp.0000000000000344
  116. Kaye A.D., Liu H., Fox C., et al. Psychiatric and Behavioral Disorders. In: Fliesher L.A.,editor. Anesthesia and Uncommon diseases. 6th Philadelphia: Saunders Elsevier, 2012: 444–469.
  117. Kudoh A. Preoperative evaluation, preparation and prognosis in depressed patients. Masui. 2010; 59(9): 1116–1127.
  118. Brent J. Critical care toxicology: diagnosis and management of the critically poisoned patient. Elsevier Health Sciences, 2005: 485–488.
  119. Руководство по клинической анестезиологии. Пер. с англ. под ред. Б.Дж. Полларда; под общ. ред. Л.В. Колотилова, В.В. Мальцева. М.: МЕДпресс-информ, 2006. [Rukovodstvo po klinicheskoy anesteziologii. Pod red. B. Dzh. Pollarda; pod obshch. red. L.V. Kolotilova, V.V. Mal’tseva. Moscow: MEDpress-inform, 2006. (In Russ)]
  120. Ragheb M. The clinical significance of lithium-nonsteroidal anti-inflammatory drug interactions. J Clin Psychopharmacol. 1990; 10(5): 350–354.
  121. Ragheb M., Powell A.L. Lithium interaction with sulindac and naproxen. J Clin Psychopharmacol. 1986; 6(3): 150–154.
  122. Finley P.R., Warner M.D., Peabody C.A. Clinical Relevance of Drug Interactions with Lithium. Clinical Pharmacokinetics. 1995; 29(3): 172–191. DOI: 10.2165/00003088-199529030-00004
  123. Spina E., Santoro V., D’Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update. Clinical Therapeutics. 2008; 30(7): 1206–1227. DOI: 10.1016/s0149-2918(08)80047-1
  124. Hemeryck A., Belpaire F. Selective Serotonin Reuptake Inhibitors and Cytochrome P-450 Mediated Drug-Drug Interactions: An Update. Current Drug Metabolism. 2002; 3(1): 13–37. DOI: 10.2174/1389200023338017
  125. Azaz-Livshits T., Danenberg H. Tachycardia, Orthostatic Hypotension and Profound Weakness Due to Concomitant Use of Fluoxetine and Nifedipine. Pharmacopsychiatry. 1997; 30(06): 274–275. DOI: 10.1055/s-2007-979508
  126. Owen J.R., Nemeroff C.B. New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine. Depress Anxiety. 1998; 7(Suppl.1): 24–32.
  127. Armahizer M.J., Seybert A.L., Smithburger P.L., et al. Drug-drug interactions contributing to QT prolongation in cardiac intensive care units. Journal of Critical Care. 2013; 28(3): 243–249. DOI: 10.1016/j.jcrc.2012.10.014
  128. Egberts A.C.G., ter Borgh J., Brodie-Meijer C.C.E. Serotonin syndrome attributed to tramadol addition to paroxetine therapy. International Clinical Psychopharmacology. 1997; 12(3): DOI: 10.1097/00004850-199705000-00010
  129. Maeda S., Tomoyasu Y., Higuchi H., et al. Independent Predictors of Delay in Emergence From General Anesthesia. Anesthesia Progress. 2015; 62(1): 8–13. DOI: 10.2344/0003-3006-62.1.8
  130. Stahl S.M. Stahl’s Essential Psychopharmacology. Neuroscientific Basis and Practical Application. Cambridge University Press. 4th 2013.
  131. Klotz U. Tramadol — the Impact of its Pharmacokinetic and Pharmacodynamic Properties on the Clinical Management of Pain. Arzneimittelforschung. 2011; 53(10): 681–687. DOI: 10.1055/s-0031-1299812
  132. Dawson J., Karalliedde L. Drug interactions and the clinical anaesthetist. European Journal of Anaesthesiology. 1998; 15(2): 172–189. DOI: 10.1111/j.0265-0215.1998.00269.x
  133. Hansen D., Syben R., Föhring U., Eyrich K. Kardiale Atropinwirkungen bei Patienten mit Antidepressiva-Medikation. AINS — Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie. 1994; 29(07): 413–416. DOI: 10.1055/s-2007-996772
  134. Martyr J.W., Orlikowski C.E.P. Epidural anaesthesia, ephedrine and phenylephrine in a patient taking moclobemide, a new monoamine oxidase inhibitor. Anaesthesia. 1996; 51(12): 1150–1152. DOI: 10.1111/j.1365-2044.1996.tb15054.x
  135. Cannizzaro E., Albisetti M., Wohlrab G., Schmugge M. Severe Bleeding Complications during Antiepileptic Treatment with Valproic Acid in Children. Neuropediatrics. 2007; 38(1): 42–45. DOI: 10.1055/s-2007-981448
  136. Israelian L.A., Lubnin A.Iu., Tseitlin A.M., et al. Hemostatic disorders caused by chronic use of valproic acid in neurosurgical patients. Thromboelastographic monitoring. Anesteziol Reanimatol. 2010; 4: 50–54.
  137. Acharya S., Bussel J.B. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol. 2000; 22(1): 62–65.
  138. Horlocker T.T., Wedel D.J., Rowlingson J.C., et al. Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy. Regional Anesthesia and Pain Medicine. 2010; 35(1): 64–101. DOI: 10.1097/aap.0b013e3181c15c70
  139. Sandson N.B., Marcucci C., Bourke D.L., et al. An Interaction Between Aspirin and Valproate: The Relevance of Plasma Protein Displacement Drug-Drug Interactions. American Journal of Psychiatry. 2006; 163(11): 1891–1896. DOI: 10.1176/ajp.2006.163.11.1891
  140. Jiang H.-Y., Chen H.-Z., Hu X.-J., et al. Use of Selective Serotonin Reuptake Inhibitors and Risk of Upper Gastrointestinal Bleeding: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology. 2015; 13(1): 42–50.e3. DOI: 10.1016/j.cgh.2014.06.021
  141. Anglin R., Yuan Y., Moayyedi P., et al. Risk of Upper Gastrointestinal Bleeding With Selective Serotonin Reuptake Inhibitors With or Without Concurrent NonSteroidal Anti-Inflammatory Use: A Systematic Review and Meta-Analysis. The American Journal of Gastroenterology. 2014; 109(6): 811–819. DOI: 10.1038/ajg.2014.82
  142. Scheitz J.F., Turc G., Kujala L., et al. Intracerebral Hemorrhage and Outcome After Thrombolysis in Stroke Patients Using Selective Serotonin-Reuptake Inhibitors. Stroke. 2017; 48(12): 3239–3244. DOI: 10.1161/strokeaha.117.018377
  143. Douros A., Ades M., Renoux C. Risk of Intracranial Hemorrhage Associated with the Use of Antidepressants Inhibiting Serotonin Reuptake: A Systematic Review. CNS Drugs. 2018; 32(4): 321–334. DOI: 10.1007/s40263-018-0507-7
  144. Shaw A., Matthews E.E. Postoperative neuroleptic malignant syndrome. Anaesthesia. 1995; 50(3): 246–247. DOI: 10.1111/j.1365-2044.1995.tb04566.x
  145. So P.C. Neuroleptic malignant syndrome induced by droperidol. Hong Kong Med J. 2001; 7: 101–10
  146. Gillman P.K. Neuroleptic malignant syndrome: Mechanisms, interactions, and causality. Movement Disorders. 2010; 25(12): 1780–1790. DOI: 10.1002/mds.23220
  147. Bhalla T., Maxey D., Sawardekar A., Tobias J.D. Anesthetic management of a pediatric patient with neuroleptic malignant syndrome. Journal of Anesthesia. 2011; 26(2): 250–253. DOI: 10.1007/s00540-011-1269-2
  148. Федеральные клинические рекомендации по диагностике и лечению шизофрении (проект). Московский НИИ психиатрии. 2013. Обсуждение на сайте Российского Общества Психиатров — psychiatr.ru. [Federal’nye klinicheskie rekomendacii po diagnostike i lecheniyu shizofrenii (proekt). Moskovskij NII psihiatrii. 2013. Obsuzhdenie na sajte Rossijskogo Obshchestva Psihiatrov — psychiatr.ru. (In Russ)]
  149. Kishimoto S., Nakamura K., Arai T., et al. Postoperative neuroleptic malignant syndrome-like symptoms improved with intravenous diazepam: a case report. Journal of Anesthesia. 2013; 27(5): 768–770. DOI: 10.1007/s00540-013-1602-z
  150. Ramamoorthy K., Hawthorne P., Downey H. Rocuronium and sugammadex: An alternative to succinylcholine for electro convulsive therapy in patients with suspected neuroleptic malignant syndrome. Journal of Anaesthesiology Clinical Pharmacology. 2011; 27(3): DOI: 10.4103/0970-9185.83687
  151. Remington G., Fervaha G., Foussias G., et al. Antipsychotic dosing: found in translation. Journal of Psychiatry & Neuroscience. 2014; 39(4): 223–231. DOI: 10.1503/jpn.130191
  152. Mailman R., Murthy V. Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity? Current Pharmaceutical Design. 2010; 16(5): 488–501. DOI: 10.2174/138161210790361461
  153. Zolezzi M. Medication management during electroconvulsant therapy. Neuropsychiatric Disease and Treatment. 2016; 12: 931–939. DOI: 10.2147/ndt.s100908
  154. O’Keane V., Meaney A.M. Antipsychotic Drugs. Journal of Clinical Psychopharmacology. 2005; 25(1): 26–31. DOI: 10.1097/01.jcp.0000150223.31007.e0
Лицензия Creative Commons

Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-ShareAlike» («Атрибуция — Некоммерческое использование — На тех же условиях») 4.0 Всемирная.

Copyright (c) 2021 ВЕСТНИК ИНТЕНСИВНОЙ ТЕРАПИИ имени А.И. САЛТАНОВА